Percutaneous iodixanol localization of pulmonary ground-glass nodules for synchronous microwave ablation and biopsy: a multicenter, retrospective, matched analysis.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: high-risk pulmonary ground-glass nodules (GGNs) who are unfit for resection
I · Intervention 중재 / 시술
synchronous MWA and biopsy were enrolled in a multicenter retrospective study from January 1, 2021, to December 31, 2022
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Analysis of the matched cohort (n=94 per group) confirmed that the iSMB group, as compared to the cSMB group, had a higher primary technique efficacy rate (100.0% 91.5%; P=0.007) and a higher positive biopsy rate (97.9% 89.4%; P=0.017). [CONCLUSIONS] Iodixanol localization during synchronous MWA and biopsy of GGNs is efficient and safe.
[BACKGROUND] Synchronous microwave ablation (MWA) and biopsy are suitable for patients with high-risk pulmonary ground-glass nodules (GGNs) who are unfit for resection.
- 표본수 (n) 108
- p-value P=0.007
- p-value P=0.030
APA
Wei Z, Yang X, et al. (2026). Percutaneous iodixanol localization of pulmonary ground-glass nodules for synchronous microwave ablation and biopsy: a multicenter, retrospective, matched analysis.. Quantitative imaging in medicine and surgery, 16(2), 158. https://doi.org/10.21037/qims-2024-2580
MLA
Wei Z, et al.. "Percutaneous iodixanol localization of pulmonary ground-glass nodules for synchronous microwave ablation and biopsy: a multicenter, retrospective, matched analysis.." Quantitative imaging in medicine and surgery, vol. 16, no. 2, 2026, pp. 158.
PMID
41669463
Abstract
[BACKGROUND] Synchronous microwave ablation (MWA) and biopsy are suitable for patients with high-risk pulmonary ground-glass nodules (GGNs) who are unfit for resection. The ablation accuracy is affected by hemorrhage and nodule displacement. We thus aimed to verify whether iodixanol localization could enhance the accuracy of the synchronous MWA and biopsy of GGNs.
[METHODS] A total of 211 continuous patients who underwent synchronous MWA and biopsy were enrolled in a multicenter retrospective study from January 1, 2021, to December 31, 2022. Patients undergoing synchronous MWA and biopsy under conventional computed tomography (CT) guidance were placed in the conventional CT guidance for synchronous MWA and biopsy (cSMB) group and those with iodixanol localization were placed in the iodixanol localization for synchronous MWA and biopsy (iSMB) group. The primary outcomes included primary technique efficacy rate (defined as complete ablation based on a CT scan at 3 months), positive biopsy rate, and complications. In addition to an analysis of the overall cohort, data were compared in propensity score matching for GGN characteristics to minimize the impact of confounding factors.
[RESULTS] Compared to the cSMB group (n=108), the iSMB group (n=103) had a higher primary technique efficacy rate (100.0% 92.6%; P=0.007) and positive biopsy rate (96.1% 88.0%, P=0.030). In the cSMB group, the rates of pneumothorax and pleural effusion were 49.1% (53/108) and 37.1% (40/108), respectively, while they were 38.8% (40/103) and 21.3% (22/103), respectively, in the iSMB group (P=0.134 and P=0.012, respectively). Analysis of the matched cohort (n=94 per group) confirmed that the iSMB group, as compared to the cSMB group, had a higher primary technique efficacy rate (100.0% 91.5%; P=0.007) and a higher positive biopsy rate (97.9% 89.4%; P=0.017).
[CONCLUSIONS] Iodixanol localization during synchronous MWA and biopsy of GGNs is efficient and safe.
[METHODS] A total of 211 continuous patients who underwent synchronous MWA and biopsy were enrolled in a multicenter retrospective study from January 1, 2021, to December 31, 2022. Patients undergoing synchronous MWA and biopsy under conventional computed tomography (CT) guidance were placed in the conventional CT guidance for synchronous MWA and biopsy (cSMB) group and those with iodixanol localization were placed in the iodixanol localization for synchronous MWA and biopsy (iSMB) group. The primary outcomes included primary technique efficacy rate (defined as complete ablation based on a CT scan at 3 months), positive biopsy rate, and complications. In addition to an analysis of the overall cohort, data were compared in propensity score matching for GGN characteristics to minimize the impact of confounding factors.
[RESULTS] Compared to the cSMB group (n=108), the iSMB group (n=103) had a higher primary technique efficacy rate (100.0% 92.6%; P=0.007) and positive biopsy rate (96.1% 88.0%, P=0.030). In the cSMB group, the rates of pneumothorax and pleural effusion were 49.1% (53/108) and 37.1% (40/108), respectively, while they were 38.8% (40/103) and 21.3% (22/103), respectively, in the iSMB group (P=0.134 and P=0.012, respectively). Analysis of the matched cohort (n=94 per group) confirmed that the iSMB group, as compared to the cSMB group, had a higher primary technique efficacy rate (100.0% 91.5%; P=0.007) and a higher positive biopsy rate (97.9% 89.4%; P=0.017).
[CONCLUSIONS] Iodixanol localization during synchronous MWA and biopsy of GGNs is efficient and safe.
같은 제1저자의 인용 많은 논문 (5)
- Evaluating Post-Progression Survival in the Context of Progression-Free Survival Benefits: A Revisit of the CodeBreaK200 Design.
- Prognostic significance and therapeutic potential of pyroptosis in gynecological malignancies.
- Integrating network pharmacology and Mendelian randomization to explore potential targets of Fufang Banmao capsule against non-small cell lung cancer.
- BLADE: Breast Lesion Analysis with Domain Expertise for DCE-MRI Diagnosis.
- Considerations on MRI-Based Stratification for Retreatment After TACE in HCC.